Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

5th Annual EurocanPlatform Meeting /
The POSEIDON trial of the EurocanPlatform project

3rd Nov 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.12.15
Views: 1943
Rating:

Dr Richard Baird - Cambridge Cancer Centre, Cambridge, UK

Dr Baird outlines the background of the POSEIDON trial of the EurocanPlatform project, an investigator-led trial in metastatic breast cancer that is hormone receptor positive and HER2-negative. The trial is examining a combination of Tamoxifen with PI-3 kinase inhibitor.

EurocanPlatform is an EC funded project bringing together 28 European cancer Institutions and organisations to work together in a unique collaboration. The centres are sharing infrastructures and collaborating on projects to help advance cancer research and treatment.

He explains how the EurocanPlatform project has been instrumental in bringing the trial to life, what challenges have been faced and what they expect for the remainder of the trial in the future.

Watch this video on the highlights of the project.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation